Brooke Hoppe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brooke Hoppe has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Carly Baehr
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota
3 shared publications - Marco Pravetoni
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, USA
3 shared publications - Dustin Hicks
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota
2 shared publications Elaine Gay
Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, North Carolina
2 shared publicationsAaron Khaimraj
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota
1 shared publication- Aaron M. LeBeau
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
1 shared publication
Latest Publications
- 10 October 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (11) , 103743
An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs
- 10 October 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (11) , 103743
An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs
- Open Access
A cationic liposome-formulated Toll Like Receptor (TLR)7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity
The U.S. opioid epidemic is an extraordinary public health crisis that started in 1990 and significantly accelerated in the last decade. Since 2020, over 100,000 fatal drug overdoses have been reported annually, and 75% of those involved fentanyl and its analogs (F/FA). Accelerating the translation of innovative, effective, and safe treatments is needed to augment existing measures to counteract such a crisis. Active immunization against F/FA and other opioids represents a promising therapeutic and prophylactic strategy for opioid use disorder (OUD) and opioid-induced overdose toxicity. Previously we demonstrated that the anti-fentanyl vaccine comprising a fentanyl-based hapten (F) conjugated to the diphtheria cross-reactive material (CRM), admixed with the novel lipidated toll-like receptor 7/8 (TLR7/8) agonist INI-4001 adsorbed on Alhydrogel ® (alum) induced high-affinity fentanyl-specific polyclonal antibodies that protected against fentanyl-induced pharmacological effects in mice, rats, and mini-pigs. Here, INI-4001 was formulated into liposomes with different surface charges, and their impact on F-CRM adsorption, INI-4001 adjuvanticity, and vaccine efficacy were explored. Additionally, as the role of innate immunity in mediating the efficacy of addiction vaccines is largely unknown, we tested these formulations on the activation of innate immunity in vitro . Cationic INI-4001 liposomes surpassed other liposomal and aluminum-based formulations of INI-4001 by enhancing the efficacy of fentanyl vaccines and protecting rats against bradycardia and respiratory depression by blocking the distribution of fentanyl to the brain. Fentanyl vaccines adjuvanted with either cationic INI-4001 liposomes or the aqueous INI-4001 adsorbed to alum induced significant surface expression of co-stimulatory molecules and maturation markers in a murine dendritic cell line (JAWS II), while the former was superior in enhancing the macrophages surface expression of CD40, CD86 and inducible nitric oxide synthase (iNOS), indicative of maturation and activation. These results warrant further investigation of liposome-based formulations of TLR7/8 agonists for improving the efficacy of vaccines targeting F/FA and other opioids of public health interest. Graphical
Open AccessA cationic liposome-formulated Toll Like Receptor (TLR)7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity
The U.S. opioid epidemic is an extraordinary public health crisis that started in 1990 and significantly accelerated in the last decade. Since 2020, over 100,000 fatal drug overdoses have been reported annually, and 75% of those involved fentanyl and its analogs (F/FA). Accelerating the translation of innovative, effective, and safe treatments is needed to augment existing measures to counteract such a crisis. Active immunization against F/FA and other opioids represents a promising therapeutic and prophylactic strategy for opioid use disorder (OUD) and opioid-induced overdose toxicity. Previously we demonstrated that the anti-fentanyl vaccine comprising a fentanyl-based hapten (F) conjugated to the diphtheria cross-reactive material (CRM), admixed with the novel lipidated toll-like receptor 7/8 (TLR7/8) agonist INI-4001 adsorbed on Alhydrogel ® (alum) induced high-affinity fentanyl-specific polyclonal antibodies that protected against fentanyl-induced pharmacological effects in mice, rats, and mini-pigs. Here, INI-4001 was formulated into liposomes with different surface charges, and their impact on F-CRM adsorption, INI-4001 adjuvanticity, and vaccine efficacy were explored. Additionally, as the role of innate immunity in mediating the efficacy of addiction vaccines is largely unknown, we tested these formulations on the activation of innate immunity in vitro . Cationic INI-4001 liposomes surpassed other liposomal and aluminum-based formulations of INI-4001 by enhancing the efficacy of fentanyl vaccines and protecting rats against bradycardia and respiratory depression by blocking the distribution of fentanyl to the brain. Fentanyl vaccines adjuvanted with either cationic INI-4001 liposomes or the aqueous INI-4001 adsorbed to alum induced significant surface expression of co-stimulatory molecules and maturation markers in a murine dendritic cell line (JAWS II), while the former was superior in enhancing the macrophages surface expression of CD40, CD86 and inducible nitric oxide synthase (iNOS), indicative of maturation and activation. These results warrant further investigation of liposome-based formulations of TLR7/8 agonists for improving the efficacy of vaccines targeting F/FA and other opioids of public health interest. Graphical
- Open Access
- 28 June 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (8) , 107502
Identification and biophysical characterization of a novel domain-swapped camelid antibody specific for fentanyl
- 28 June 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (8) , 107502
Open AccessIdentification and biophysical characterization of a novel domain-swapped camelid antibody specific for fentanyl
- Open Access
- 17 February 2023
- Published by Elsevier in The American Journal of Pathology
- Vol. 193 (5) , 532-547
Transcriptional Profiling Supports the Notochordal Origin of Chordoma and Its Dependence on a TGFB1-TBXT Network
- 17 February 2023
- Published by Elsevier in The American Journal of Pathology
- Vol. 193 (5) , 532-547
Open AccessTranscriptional Profiling Supports the Notochordal Origin of Chordoma and Its Dependence on a TGFB1-TBXT Network
- Open Access
- 1 December 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (49) , 45336-45340
Investigation of the Effect of Turn Residues on Tetrapeptide Aldol Catalysts with β-Turn Propensity
Peptide catalysts for a wide diversity of reaction types contain a common motif-residues that bias the sequence toward beta-turn secondary structure. In this work, we explore what role that secondary structure plays in the catalysis of aldol reactions for primary amine tetrapeptide aldol catalysts. Using a lead tetrapeptide beta-turn catalytic sequence, we varied the i + 1 and i + 2 residues to amino acids that would affect the beta-turn propensity. We then studied the correlation between secondary structure, aldol rate enhancement, and stereoselectivity of the reaction between hydroxyacetone and 4-nitrobenzaldehyde. Using the i + 3 amide chemical shift as a measure of beta-turn character, we found a rough correlation between the peptide structure and reaction kinetics but minimal effect on stereoselectivity. These trends may help aid the design of future catalytic sequences.
- 1 December 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (49) , 45336-45340
Open AccessInvestigation of the Effect of Turn Residues on Tetrapeptide Aldol Catalysts with β-Turn Propensity
Peptide catalysts for a wide diversity of reaction types contain a common motif-residues that bias the sequence toward beta-turn secondary structure. In this work, we explore what role that secondary structure plays in the catalysis of aldol reactions for primary amine tetrapeptide aldol catalysts. Using a lead tetrapeptide beta-turn catalytic sequence, we varied the i + 1 and i + 2 residues to amino acids that would affect the beta-turn propensity. We then studied the correlation between secondary structure, aldol rate enhancement, and stereoselectivity of the reaction between hydroxyacetone and 4-nitrobenzaldehyde. Using the i + 3 amide chemical shift as a measure of beta-turn character, we found a rough correlation between the peptide structure and reaction kinetics but minimal effect on stereoselectivity. These trends may help aid the design of future catalytic sequences.